ArticleCureus2026
Quality Assessment of an Immunotherapy Toxicity Clinic: A Clinical Audit at Castle Hill Hospital Evaluating Adherence to Clinical Guidelines, Documentation Standards, and Clinical Outcomes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapy has developed as a cancer treatment by enhancing the body's immune system to attack cancer cells. Checkpoint inhibitors (e.g., programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte antigen-4 (CTLA-4)) have shown very good outcomes in treating several tumour types. However, their use can cause a unique category of toxicities, immune-related adverse events (irAEs). These differ from chemotherapy-related side effects, may affect any organ, and require specialised recognition and management. This audit reviews the performance of a dedicated Immunotherapy Toxicity Clinic at Queen's Centre for Oncology and Haematology, Hull University Teaching Hospitals. It includes all oncology patients referred between January 1 and June 30, 2024. Using a validated clinical tool, we assess the types, severity, and outcomes of irAEs, as well as adherence to protocols and quality of documentation. This work highlights current practice, identifies gaps, and provides a quality improvement tool for managing patients on immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.